metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology BUN/creatinine ratio associated with mortality in patients with cirrhosis and ac...
Journal Information
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Full text access
BUN/creatinine ratio associated with mortality in patients with cirrhosis and acute kidney injury.
Visits
515
Diego F. Abendaño-Rivera1, Cristian Y Sánchez-Sánchez1, Karina Cazarin-Chávez1, Paloma M. Diego-Salazar1, Daniel Santana-Vargas2, María F. Higuera-De La Tijera1, José L. Pérez-Hernández1
1 Department of Gastroenterology and Hepatology General Hospital of Mexico “Dr. Eduardo Liceaga", Mexico City, Mexico
2 Research Department General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City, Mexico
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S2

Abstracts Asociación Mexicana del Hígado (AMH) 2023

More info
Introduction and Objectives

Cirrhosis is a prevalent disease worldwide, with complications such as acute kidney injury (AKI) that increase the risk of fatal outcomes. A high BUN/creatinine ratio (IBC) has been associated with mortality in other diseases Therefore, evaluating this index in patients with cirrhosis could predict mortality. To determine whether a high BUN/creatinine ratio is associated with mortality in patients with cirrhosis and AKI.

Materials and Patients

Retrospective analysis was conducted on a cohort of cirrhotic patients with and without AKI, calculating the IBC and assessing its association with mortality.

Results

A total of 201 patients with cirrhosis were included, of whom 106 were male (52.73%), with a mean age of 55±10.4 years. The distribution of Child Pugh scores was as follows: A (25, 12.43%), B (70, 34.82%), and C (106, 52.73%); the mean MELD-Na score was 21.8±9.45. The cumulative mortality rate at 28 days was 37 (18.4%) and at 90 days was 39 (24.4%). The model was not significant at 28 days but was significant at 90 days with a X2 value of 48.18 (2) and p<0.001.

At 90 days, the model was significant with a x2 value of 49.7 (2) and p<0.001, with an OR (IBC) of 2.78 (1.08-7.11, 95% CI, p=0.33), and for AKI OR of 7.97 (2.2-28.8, 95% CI, p=0.02) (Figure 1). Considering either factor present, the model was significant at 28 days with a X2 of 27.75 (1) and p<0.001, with an OR of 7.2 (3-17.3, p<0.001), and at 90 days with a X2 of 35.59 (1) and p<0.001, with an OR of 6.67 (3.23-13.76, p<0.001).

Conclusions

The Cox proportional hazards model was used to compare factors associated with mortality separately for AKI (present vs. absent) and IBC (>20 mg/dl vs. <20 mg/dl) at 28 and 90 days, as well as if both factors were present. The model was considered significant if the p-value was less than 0.5. The study concluded that a higher IBC (>20 mg/dl) could predict mortality in patients with cirrhosis, as the odds ratios at 28 and 90 days were significant.

Full Text

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Figure 1. IBC and AKI at 90 days associated with mortality.

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2024.101437
No mostrar más